Clinical trials: MDD
Major Depressive Disorder
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).
- Trial name
- NCT00775203
- Testing
- Trazodone Hydrochloride (HCl) Extended-Release Tablets
- Where
- 36 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Labopharm Inc.
Major Depressive Disorder (MDD)
NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient
Transcranial Magnetic Stimulation (TMS) Therapy is a non-invasive procedure that uses magnetic pulses to stimulate the cortex (brain) to treat Major Depressive Disorder (MDD).
- Trial name
- NCT06772987
- Testing
- Accelerated rTMS treatment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- NeuroQore Inc.
Depressive Disorder, Major
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
The primary purpose is to study the efficacy, safety, and tolerability of LY2216684 as an adjunctive treatment for participants with major depressive disorder (MDD), who were identified as partial responders to an adequate course…
- Trial name
- NCT00840034
- Testing
- LY2216684
- Where
- 24 sites in United States
- Volunteers
- 227 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder (MDD)
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.
- Trial name
- NCT00448292
- Testing
- PRX-00023
- Where
- 21 sites in United States
- Volunteers
- 330 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Major Depressive Disorders
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
Primary objective: To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD).
- Trial name
- NCT00855530
- Testing
- amibegron (SR58611A)
- Where
- 11 sites in Argentina, Chile and 9 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Major Depressive Disorder
Safety, Tolerability and Pharmacokinetics Study of LY03005
The purpose of this study is to evaluate the safety and tolerability of escalating single oral doses of LY03005 in healthy subjects and to characterize the pharmacokinetics (PK) of escalating single oral doses of LY03005.
- Trial name
- LY03005SAD (NCT02055300)
- Testing
- LY03005, Meal, Pristiq
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depression, Anxiety
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial.
- Trial name
- UHS (NCT01632267)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Assurex Health Inc.
Major Depressive Disorder
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
- Trial name
- NCT05655507
- Testing
- Zuranolone
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Biogen
Major Depressive Disorder
Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology
The purpose of this study was to evaluate the feasibility and compliance with a novel method for assessing mood and cognition in participants with major depressive disorder (MDD).
- Trial name
- NCT03067506
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Takeda
Insomnia
Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro
To demonstrate overall improvement of insomnia in subjects treated with zolpidem tartrate extended-release (Ambien CR) and escitalopram (Lexapro) vs. subjects treated with placebo and escitalopram at 2 months.
- Trial name
- NCT00296179
- Testing
- zolpidem tartrate
- Volunteers
- 372 people
- Sponsor
- Sanofi
Major Depressive Disorder
Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response
The purpose is to assess the response of add-on therapy, based on CGI-I scale, at 4 weeks, in patients with MDD who had an inadequate disease control with antidepressant medication.
- Trial name
- MADDRE (NCT01397903)
- Where
- 27 sites in Greece
- Volunteers
- 545 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- orvepitant MDD (NCT00880399)
- Testing
- orvepitant
- Where
- 20 sites in United States, Canada
- Volunteers
- 328 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Major Depression, Dysthymia
Online System for Identifying and Addressing Teen Depression in Primary Care
A novel web-based module (Teen Depression Module or TDM)has been created for assisting primary care providers (PCPs) in screening for and addressing and referring teens with depression.
- Conditions
- Major Depression, Dysthymia, Depressive Symptoms
- Trial name
- Depression (NCT04489485)
- Testing
- Teen Depression Module used for care
- Where
- United States
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- Total Child Health, Inc.
Depressive Disorder, Major
Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder
The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder.
- Trial name
- NCT00300378
- Testing
- desvenlafaxine 50 mg, desvenlafaxine 100 mg
- Where
- 43 sites in Croatia, Estonia and 8 more
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer